Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/16413
|
| Title: | TCOG T3221 study: The registry of genetic alterations of Taiwan biliary tract cancer |
| Authors: | Chiang, N;Hsu, C;Chen, J;Dai, M;Bai, L;Yen, C;Wang, T;Hsieh, Y;Lin, J;Chiu, T;Cheng, H;Yang, Y;Hsiao, C;Chen, L;Chen, M |
| Contributors: | National Institute of Cancer Research;Institute of Population Health Sciences |
| Abstract: | Background :Recent advances in oncology drug development and next-generation sequencing (NGS)-based genomic profiling have greatly improved treatment precision for advanced biliary tract cancer (BTC). The current registration study (NCT05036486) was initiated to evaluate targetable genetic alterations in specific BTC groups in Taiwan. Methods: A total of 264 tumor tissues from 194 adenocarcinoma or adenosquamous carcinoma of intrahepatic cholangiocarcinoma (ICC), 38 extrahepatic cholangiocarcinoma (ECC), and 32 gallbladder cancer (GBC) were sequenced with a clinical-graded panel ACTOnco®+ encompassing 440 cancer-related genes. Therapeutic evidence of predictive biomarkers was categorized into levels 1-4 using the Memorial Sloan Kettering Precision Oncology Knowledge Base classification. Baseline characteristics, previous history, and subsequent treatment and outcomes were collected at six-month intervals until either expiration or five years following enrollment. Results: The most commonly altered genes in the entire cohort were TP53 (45%), KRAS (23%), CDKN2A (14%), ARID1A (13%), ERBB2(HER2, 11%), and BAP1 (7%). Therapeutic biomarkers with evidence levels 1-4 were identified in 58%, 58%, and 56% of patients with ICC, ECC, and GBC, respectively. Among the ICC group, 28.5% harbored level 1 biomarkers, including the IDH1R132C mutation (11.3%), FGFR2 fusions (10.5%), tumor mutation burden-high (TMB H, 5.7%), RET fusion (0.5%), and BRAFV600E mutation (0.5%), which occurred mutually exclusively. While level 1 therapeutic biomarkers are rarely found in non-ICC patients, such as 1 (2.6%) IDH1R132C mutation in ECC and 1 (3.1%) TMB-H in GBC, there is a notably higher prevalence of targetable HER2 alterations, including gene mutations and amplifications, in GBC (28.1%) compared to ICC (10.5%) and ECC (7.7%). Conclusions: Resutls from the extensive multi-center study in Taiwan on tissue NGS for specific BTC populations could become a benchmark for reimbursed diagnostic tests. |
| Date: | 2024-10 |
| Relation: | Annals of Oncology. 2024 Oct;35(Suppl. 3):S1355. |
| Link to: | http://dx.doi.org/10.1016/j.annonc.2024.07.608 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001345709300196 |
| Appears in Collections: | [陳立宗] 會議論文/會議摘要
[姜乃榕] 會議論文/會議摘要
[蕭金福] 會議論文/會議摘要
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI001345709300196.pdf | | 86Kb | Adobe PDF | 18 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
